Analyzing New Drug Developments and Clinical Effectiveness in Targeted Cancer Therapies
DOI:
https://doi.org/10.56294/hl2025606Keywords:
Targeted Cancer Therapies, Drug Developments, Clinical Effectiveness, Precision Medicine, BiomarkersAbstract
The quick progress in tailored cancer treatments has changed the field of oncology and opened up new ways to treat each patient individually. This essay looks at new drugs that have been made recently and how well they work in the real world. It focuses on focused therapies that try to stop certain molecular processes that are linked to cancer spreading. With the rise of precision medicine programs, it is important to understand how these treatments work, how well they work, and how safe they are in order to improve patient results. New focused treatments, like monoclonal antibodies, small molecule inhibitors, and CAR-T cell therapies, have shown potential in treating a number of cancers, such as breast, lung, and blood cancers. This study looks at the most important clinical trials that proved the effectiveness of the drugs that were approved in the last five years. One example is how the approval of osimertinib for EGFR-mutated non-small cell lung cancer (NSCLC) has made patients' chances of surviving and quality of life much better. In the same way, new drugs that target the BRAF and MEK pathways have changed the way cancer is treated. The study also looks at problems that come with tailored treatments, such as drug resistance, side effects, and the need for additional tests. Even though targeted treatments work, patients often develop secondary changes that make them resistant. To get around these problems, researchers are still working on combination therapies and new drugs. The study also stresses how important it is to find biomarkers that can help predict how well a treatment will work, which is necessary for making sure that each patient gets the best possible care. The study also talks about the economic effects of tailored treatments, comparing their high research costs to the chance of better patient results and lower total healthcare costs. As focused medicines keep getting better, it is very important for drug companies, governmental bodies, and healthcare workers to work together to make sure that everyone has equal access to these new treatments.
References
] Saeed, R.F.; Awan, U.A.; Saeed, S.; Mumtaz, S.; Akhtar, N.; Aslam, S. Targeted Therapy and Personalized Medicine. Cancer Treat Res. 2023, 185, 177–205.
[2] Peng, S.; Xiao, F.; Chen, M.; Gao, H. Tumor-Microenvironment-Responsive Nanomedicine for Enhanced Cancer Immunotherapy. Adv. Sci. 2022, 9, e2103836.
[3] Mendes, I.; Vale, N. How Can the Microbiome Induce Carcinogenesis and Modulate Drug Resistance in Cancer Therapy? Int. J. Mol. Sci. 2023, 24, 11855.
[4] Costa, B.; Vale, N. Exploring HERV-K (HML-2) Influence in Cancer and Prospects for Therapeutic Interventions. Int. J. Mol. Sci. 2023, 24, 14631.
[5] Haque, M.; Shakil, M.S.; Mahmud, K.M. The Promise of Nanoparticles-Based Radiotherapy in Cancer Treatment. Cancers 2023, 15, 1892.
[6] Glasgow, M.D.; Chougule, M.B. Recent Developments in Active Tumor Targeted Multifunctional Nanoparticles for Combination Chemotherapy in Cancer Treatment and Imaging. J. Biomed. Nanotechnol. 2015, 11, 1859–1898.
[7] Dang, Y.; Guan, J. Nanoparticle-Based Drug Delivery Systems for Cancer Therapy. Smart Mater. Med. 2020, 1, 10–19.
[8] Di Stefano, A. Nanotechnology in Targeted Drug Delivery. IJMS 2023, 24, 8194.
[9] Chamundeeswari, M.; Jeslin, J.; Verma, M.L. Nanocarriers for Drug Delivery Applications. Environ. Chem. Lett. 2019, 17, 849–865.
[10] Pushpalatha, R.; Selvamuthukumar, S.; Kilimozhi, D. Nanocarrier Mediated Combination Drug Delivery for Chemotherapy—A Review. J. Drug Deliv. Sci. Technol. 2017, 39, 362–371.
[11] Khizar, S.; Alrushaid, N.; Alam Khan, F.; Zine, N.; Jaffrezic-Renault, N.; Errachid, A.; Elaissari, A. Nanocarriers Based Novel and Effective Drug Delivery System. Int. J. Pharm. 2023, 632, 122570.
[12] Shah, A.; Aftab, S.; Nisar, J.; Ashiq, M.N.; Iftikhar, F.J. Nanocarriers for Targeted Drug Delivery. J. Drug Deliv. Sci. Technol. 2021, 62, 102426.
[13] Ren, H.; He, Y.; Liang, J.; Cheng, Z.; Zhang, M.; Zhu, Y.; Hong, C.; Qin, J.; Xu, X.; Wang, J. Role of Liposome Size, Surface Charge, and PEGylation on Rheumatoid Arthritis Targeting Therapy. ACS Appl. Mater. Interfaces 2019, 11, 20304–20315.
[14] Zhang, Y.; Sun, C.; Wang, C.; Jankovic, K.E.; Dong, Y. Lipids and Lipid Derivatives for RNA Delivery. Chem. Rev. 2021, 121, 12181–12277.
[15] Li, S.; Wang, F.; Li, X.; Chen, J.; Zhang, X.; Wang, Y.; Liu, J. Dipole Orientation Matters: Longer-Circulating Choline Phosphate than Phosphocholine Liposomes for Enhanced Tumor Targeting. ACS Appl. Mater. Interfaces 2017, 9, 17736–17744.
[16] Ma, K.; Xu, S.; Tao, T.; Qian, J.; Cui, Q.; Rehman, S.U.; Zhu, X.; Chen, R.; Zhao, H.; Wang, C.; et al. Magnetosome-Inspired Synthesis of Soft Ferrimagnetic Nanoparticles for Magnetic Tumor Targeting. Proc. Natl. Acad. Sci. USA 2022, 119, e2211228119.
[17] Zhou, H.; Lu, X.; Du, C.; Zhou, Z.; Feng, J.; Liang, Z.; Xu, Y.; Qiu, X.; Shen, Z. Cycloacceleration of Reactive Oxygen Species Generation Based on Exceedingly Small Magnetic Iron Oxide Nanoparticles for Tumor Ferroptosis Therapy. Small 2022, 18, 2202705.
[18] Biffi, S.; Voltan, R.; Bortot, B.; Zauli, G.; Secchiero, P. Actively Targeted Nanocarriers for Drug Delivery to Cancer Cells. Expert. Opin. Drug Deliv. 2019, 16, 481–496.
[19] Roex, M.C.J.; Hageman, L.; Veld, S.A.J.; van Egmond, E.; Hoogstraten, C.; Stemberger, C.; Germeroth, L.; Einsele, H.; Falkenburg, J.H.F.; Jedema, I. A Minority of T Cells Recognizing Tumor-Associated Antigens Presented in Self-HLA Can Provoke Antitumor Reactivity. Blood 2020, 136, 455–467.
[20] Murray, E.R.; Brown, N.F.; Howard, P.; Masterson, L.; Zammarchi, F.; van Berkel, P.H.; Marshall, J.F. Marshall. Abstract 958: Effective targeting of pancreatic ductal adenocarcinoma metastases with an integrin αvβ6-targeting pep-tide-drug conjugate. Cancer Res. 2021, 81, 958.
[21] Li, K.; Liu, C.-J.; Zhang, X.-Z. Multifunctional Peptides for Tumor Therapy. Adv. Drug Deliv. Rev. 2020, 160, 36–51.
[22] Yang, J.; Li, Q.; Zhou, M.; Li, X.; Huang, Y.; Yang, N.; Zhou, Z. Concurrent impairment of nucleus and mito-chondria for synergistic inhibition of cancer metastasis. Int. J. Pharm. 2021, 608, 0378–5173.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Sneh Lata, Karan Pandre, Laxmidhara Maharana, Prateek Garg, Sumeet Kaur, Deepa P (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.
